Zeitschriftenartikel (155)

Gschwind, A.; Prenzel, N.; Ullrich, A.: Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal Transactivation. Cancer Research 62 (21), S. 6329 - 6336 (2002)
Buschbeck, M.; Eickhoff, J.; Sommer, M. N.; Ullrich, A.: Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway. Journal of Biological Chemistry 277 (33), S. 29503 - 29509 (2002)
Daub, H.; Blencke, S.; Habenberger, P.; Kurtenbach, A.; Dennenmoser, J.; Wissing, J.; Ullrich, A.; Cotten, M.: Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. Journal of Virology 76 (16), S. 8124 - 8137 (2002)
Zeng, J. Z.; Wang, H. Y.; Chen, Z. J.; Ullrich, A.; Wu, M. C.: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene 21 (32), S. 4932 - 4943 (2002)
Wallasch, C.; Crabtree, J. E.; Bevec, D.; Robinson, P. A.; Wagner, H.; Ullrich, A.: Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. Biochemical and Biophysical Research Communications 295 (3), S. 695 - 701 (2002)
Casanova, M. L.; Larcher, F.; Casanova, B.; Murillas, R.; Fernandez-Acenero, M. J.; Villanueva, C.; Martinez-Palacio, J.; Ullrich, A.; Conti, C. J.; Jorcano, J. L.: A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Research 62 (12), S. 3402 - 3407 (2002)
Cheburkin, Y. V.; Knyazeva, T. G.; Peter, S.; Knyazev, Y. P.; Karelin, M. I.; Shkolnik, M. I.; Evtushenko, V. I.; Hanson, K.; Ullrich, A.; Knyazev, P. G.: Molecular portrait of human kidney carcinomas: The cDNA microarray profiling of kinases and phosphatases involved in the cell signaling control. Molecular Biology 36 (3), S. 376 - 384 (2002)
Marchetti, A.; Tinari, N.; Buttitta, F.; Chella, A.; Angeletti, C. A.; Sacco, R.; Mucilli, F.; Ullrich, A.; Iacobelli, S.: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Research 62 (9), S. 2535 - 2539 (2002)
Shawver, L. K.; Slamon, D.; Ullrich, A.: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 (2), S. 117 - 123 (2002)
Bange, J.; Prechtl, D.; Cheburkin, Y.; Specht, K.; Harbeck, N.; Schmitt, M.; Knyazeva, T.; Müller, S.; Gärtner, S.; Sures, I. et al.; Wang, H. Y.; Imyanitov, E.; Haring, H. U.; Knayzev, P.; Iacobelli, S.; Hofler, H.; Ullrich, A.: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Research 62 (3), S. 840 - 847 (2002)
Strack, V.; Krutzfeldt, J.; Kellerer, M.; Ullrich, A.; Lammers, R.; Haring, H. U.: The protein-tyrosine-pbosphatase SHP2 is phosphorylated on serine residues 576 and 591 by protein kinase C Isoforms alpha, beta 1, beta 2, and eta. Biochemistry 41 (2), S. 603 - 608 (2002)
Neznanov, N.; Chumakov, K. P.; Ullrich, A.; Agol, V. I.; Gudkov, A. V.: Unstable receptors disappear from cell surface during poliovirus infection. Medical Science Monitor 8 (10), S. 391 - 396 (2002)
Ullrich, A.: Molecular targets in cancer therapy and their impact on cancer management. Oncology 63 (Suppl. 1), S. 1 - 5 (2002)
Zwick, E.; Bange, J.; Ullrich, A.: Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine 8 (1), S. 17 - 23 (2002)
Hackel, P. O.; Gishizky, M.; Ullrich, A.: Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biological Chemistry 382 (12), S. 1649 - 1662 (2001)

Konferenzbeitrag (1)

Thussbas, C.; Nahrig, J.; Streit, S.; Bange, J.; Kates, R.; Ulm, K.; Kiechle, M.; Hoefler, H.; Ullrich, A.; Harbeck, N.: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. ASCO Annual Meeting, 2006. Meeting Abstracts, S. 34S - 34S (2006)

Meeting Abstract (8)

Meeting Abstract
Orfi, Z.; Falcenberg, M.; Eros, D.; Orfi, L.; Keri, G.; Ullrich, A.: Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 791, S. S190 - S191. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)
Meeting Abstract
Sommer, A.; Mickler, F.; Herrmann, A.; Hermawan, A.; Braeuchle, C.; Wagner, E.; Knayzev, P.; Ullrich, A.; Roidl, A.: Tamoxifen resistance can be overcome by salinomycin treatment. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 632, S. S151 - S151. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)
Meeting Abstract
Sperl, B.; Abraham, R.; Bussemer, J.; Wallasch, C.; Schwaiger, M.; Ullrich, A.: Visualization of tumor formation in the WAP-TGFa/FGFR4Arg385 KI breast cancer mouse model. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 417, S. S99 - S100. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)
Meeting Abstract
Torka, R.; Penzes, K.; Baumann, C.; Gusenbauer, S.; Szabadkai, I.; Orfi, L.; Keri, G.; Ullrich, A.: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors - suggestion of combination therapy. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 801, S. S193 - S194. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)
Zur Redakteursansicht